刘婷婷

文章来源: 发布时间:2023-07-04 浏览次数:次

undefined

姓名:刘婷婷

职称:校聘副教授,硕士生导师

联系邮箱:liutingting@sdfmu.edu.cn; 15853121615@163.com

课题组主页:http://www.x-mol.com/groups/tina-liu


学习经历:

2009.09~2013.06延边大学药学院,药学,学士

2013.09~2018.12山东大学药学院,药物化学,硕博连读

2017.11~2018.11 UT Southwestern Medical Center,化学生物学,访问学者


工作经历:

2019.09~至今百度开云体育app药学院,药物化学,副教授


研究方向:

1.靶向肿瘤小分子荧光探针的设计、合成及评价研究;

2.靶向肿瘤的小分子抑制剂的设计、合成及评价研究。


主要学术任职:

1.山东生物医学工程学会医美药分子工程专业委员会,委员;

2.J. Med. Chem.,Eur. J. Med. Chem.等期刊审稿人


主要获奖情况:

1.山东省第十届高校青年教师教学大赛优秀奖,2022;

2.山东省高校创新创业类精品微课微课比赛二等奖2022

3.山东省课程思政示范案例三等奖,2021

4.于金明科技创新奖,2021;

5.第八届全国大学生基础医学创新实验大赛获东部赛区优秀奖2021

6.第九届山东省大学生医药生物技术技能大赛项目并获一等奖及优秀指导教师2021


主要科研课题:

1.国家自然科学基金青年基金项目,8210131454,新型BRD4荧光探针的构建及其在乳腺癌成像分析中的应用研究,2022.01-2024.1230万元,主持。

2.山东省自然科学基金青年项目,ZR2020QH344,新型环境敏感型Mcl-1荧光探针的设计、合成及成像应用研究,2021.01-2023.1214万元,主持。

3.山东省医药卫生科技发展计划项目,2019WS393,新型环境敏感型Mcl-1荧光探针的设计、合成及生物成像应用研究,2020.06-2022.062万元,主持。


近五年代表性论文(限第一作者和通讯作者):

1. Yuqi Gao1,**, Qiao Liu1, Cong Song, Shubin Song, Chengsen Tian, Jianjun Li, Wenjie Liu, Mingyu Cheng, Sitao Zhang, Xu Wang, Chengcai Xia,Tingting Liu*. Achieving Theranostic Probes Targeting BRD3/BRD4 for Imaging and Therapy of Tumor.European Journal of Medicinal Chemistry, 2025, 283, 117151.(一区)

2.Yuqi Gao#, Jie Zhang#, Jianjun Li, Shubin Song, Sitao Zhang, Qiao Liu, Xu Wang, Jinbo Zhao, Chengcai Xia, Yuliang Xiao*,Tingting Liu*. Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor.European Journal of Medicinal Chemistry, 2023, 257, 115478.(一区)

3. Wenwen Cao, Yu Zhu, Fapu Wu, Yang Tian, Zhaoming Chen, Weijia Xu, Senyao Liu,Tingting Liu*, and Hu Xiong*, Three Birds with One Stone: Acceptor Engineering of Hemicyanine Dye with NIR-II Emission for Synergistic Photodynamic and Photothermal Anticancer Therapy. Small, 2022,18, 2204851.(一区)

4. Yuqi Gao#, Jie Zhang#, Jianjun Li, Shubin Song, Sitao Zhang, Qiao Liu, Xu Wang, Jinbo Zhao, Chengcai Xia, Yuliang Xiao*,Tingting Liu*. Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor. European Journal of Medicinal Chemistry, 2023, 257, 115478.(一区)

5. Jie Zhang, Yuqi Gao, Zipeng Zhang, Jinbo Zhao, Wenshuang Jia, Chengcai Xia, Fugang Wang*,Tingting Liu*,Multi-therapies Based on PARP Inhibition: Potential TherapeuticApproaches for Cancer Treatment.Journal Medicinal Chemistry, 2022. 65, 16099−16127.(一区)

6. Zheng Zhang#, Xiaolan Xing#, Peng Guan, Shubin Song, Guirong You, Chengcai Xia,Tingting Liu*. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.European Journal of Medicinal Chemistry, 2021, 217, 113314.(一区)

7.Tingting Liu*, Yichao Wan, Yuliang Xiao, Chengcai Xia, Guiyun Duan. Dual-target inhibitors based on HDACs: Novel antitumor agents for cancer therapy.Journal of Medicinal Chemistry,2020, 63, 8977-9002.(一区)


上一篇:毛比明

下一篇:李玉磊

版权所有:百度开云体育app(山东省医学科学院)药学院(药物研究所)鲁ICP备19027497号-1

Baidu
map